The symposium, opened by Professor Enzo Porrello and Professor Christine Wells, co-chairs of the MACH Cell and Gene Therapies committee, featured five comprehensive sessions covering a range of topics:
- Emerging Technologies and Therapies
- Industry Perspectives
- The Current Investor Climate
- Local Clinical Trials
- The Patient Voice
Highlights of the event included presentations of onshore developments from renowned researchers such as Professor Clare Parish from the Florey Institute and Associate Professor Samantha Ginn from the Children’s Medical Research Institute. Industry leaders from CSL, Messenger Bio, and Cell Therapies provided valuable insights into the commercial landscape of cell and gene therapies.
A panel discussion on the current investor climate featured experts from Tenmile and Brandon Capital, offering attendees a glimpse into the financial aspects of bringing these innovative therapies to market.
The symposium also shone a spotlight on local clinical trials, with presentations from the Centre for Eye Research Australia, Arovella Therapeutics, the Royal Children’s Hospital, and the Peter MacCallum Cancer Centre.
Perhaps most importantly, the event concluded with a session dedicated to the patient voice, featuring testimonials from patients and healthcare professionals alike. This session grounded the scientific and commercial discussions in the real-world impact of these therapies.
The MACH Advances in Cell and Gene Therapies symposium represented a significant opportunity for knowledge sharing and networking in this crucial field of medical research. With Australia positioning itself at the forefront of cell and gene therapy development, this event played a vital role in shaping the future of healthcare in the country and beyond.
The symposium was followed by a networking session, allowing participants to forge new connections and discuss potential collaborations in this exciting field.
The event was generously sponsored by CSL and MCRI reNEW, and was organised on behalf of the MACH Cell and Gene Therapies committee.